<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#x09;&#x09;&#x09;&#x09;// gene products //&#x0A;" />
                    <role n="1" descr="situation of becoming abundant&#x0A;" />
                    <role n="2" descr="location referring to organ, vitro&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>Adult T cells, which are at rest in normal conditions, have the ability to proliferate strongly transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab-/-peripheral T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>After androgens have been removed and anti-androgen treatment, androgen tumour cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>HSC continued to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>HSC is able to continue to proliferate strongly in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Our observations illustrate that ingenue T cells of adults is endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>The capacity of HDCD4+ T cells specific to HIV in viremics patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>The ingenue T cells of adults regained the ability to proliferate the when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>The treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>adult naive T cells, which are at rest in normal conditions, will proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>prostate cancer cells respond to androgen may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>stat5ab-/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the full wild-length Stat5a type (picture 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>stat5ab/-peripheral T cells, which are at rest under normal conditions, will proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splenic transplant fetal cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splate transplant feet cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, feet cells transplanted intrasplenically stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, intrasplintly transplanted fetal cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>In addition, CD4+ HIV T cells has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>Treatment of angiogen prostate cancer cells of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>Treatment of angiogen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>Treatment of ingenue T cells for adults of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>adult T cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>the human placenta, which are at rest under normal conditions, will proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
